Drug Profile


Alternative Names: 1580RB; Bestatin; NK 421; Ubestatin

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Eiger BioPharmaceuticals, Inc.; Nippon Kayaku
  • Class Antineoplastics; Branched-chain amino acids; Dipeptides; Essential amino acids; Small molecules
  • Mechanism of Action Aminopeptidase B inhibitors; Aminopeptidase inhibitors; Immunostimulants; Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute nonlymphocytic leukaemia
  • Phase II Lymphoedema; Pulmonary arterial hypertension
  • Preclinical Inflammation
  • Discontinued HIV infections

Most Recent Events

  • 15 May 2017 Eiger BioPharmaceuticals completes enrolment in the phase-II LIBERTY trial for Pulmonary arterial hypertension in Canada and USA (PO)
  • 23 Mar 2017 Eiger BioPharmaceuticals has a patent pending for ubenimex for Pulmonary arterial hypertension in Europe
  • 23 Mar 2017 Eiger BioPharmaceuticals has patent protection for ubenimex for Pulmonary arterial hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top